Skip to main content

Diabetes Care Devices Market Set to Soar Past USD 57.67 Billion by 2030

The global Diabetes Care Devices market size is expected to reach USD 57.67 billion by 2030 and exhibit a CAGR of 8.7% in the forecast period (2023−2030), according to Skyquest’s latest research report. The increasing prevalence of diabetes worldwide, growing awareness about diabetes management and the importance of regular monitoring, technological advancements in diabetes care devices, rising healthcare expenditure and favourable reimbursement policies fuel the market’s growth.

Westford, USA, Aug. 15, 2023 (GLOBE NEWSWIRE) — According to SkyQuest’s latest global research of the Diabetes Care Devices market, increasing adoption of continuous glucose monitoring (CGM) systems, growing demand for insulin delivery devices, integration of advanced technologies such as artificial intelligence (AI) and Internet of Things (IoT) in diabetes care devices, development of user-friendly and portable devices, emphasis on personalized diabetes management solutions, rising focus on remote monitoring and telemedicine in diabetes care are the market trends promoting the market’s growth.

Browse in-depth TOC on “Diabetes Care Devices Market”

  • Pages – 157
  • Tables – 62
  • Figures – 75

Diabetes care devices are medical devices that help people with diabetes manage their condition. They can be used to monitor blood glucose levels, deliver insulin, and track other aspects of diabetes management. Diabetes care devices can help people with diabetes live healthier and more active lives.

Get a sample copy of this report:

https://www.skyquestt.com/sample-request/diabetes-care-devices-and-drugs-market

Prominent Players in Diabetes Care Devices Market

  • Abbott
  • Dexcom
  • Medtronic
  • Insulet
  • Tandem Diabetes Care
  • Roche
  • Johnson & Johnson
  • LifeScan
  • Ascensia Diabetes Care
  • Nipro Diagnostics
  • Becton, Dickinson and Company
  • Sanofi
  • Terumo Corporation
  • Ypsomed
  • Arkray
  • MicroGene
  • Dr. Morepen
  • Sinocare

Self-Monitoring Blood Glucose Device Demand is to Grow Substantially in the Forecast Period

Self-monitoring blood glucose devices dominated the global market owing to their quick and convenient measurements. It also allows patients to monitor their glucose levels at home or on the go. With the increasing prevalence of diabetes and growing awareness about self-management, SMBG devices are expected to continue dominating the market.

Browse summary of the report and Complete Table of Contents (ToC):

https://www.skyquestt.com/report/diabetes-care-devices-and-drugs-market

Homecare Settings is the Leading End-User Segment

In terms of end-user, the homecare setting is the leading segment due to the demand for convenience and patient preference. In addition, there is an increasing focus on empowering individuals with diabetes to participate in their own care actively. Homecare settings support this trend by enabling patients to take control of their diabetes management, promoting self-monitoring and adherence to treatment plans.

North America is the leading Market Due to Technological Advancements

Region-wise, North America is one of the largest growing markets with a huge emphasis on diabetes treatment. The region has been at the forefront of technological advancements and innovation in diabetes care devices. It is home to several prominent manufacturers and research institutions focused on developing advanced devices for diabetes management.

A recent report thoroughly analyzes the major players operating within the Diabetes Care Devices market. This comprehensive evaluation has considered several crucial factors, such as collaborations, mergers, innovative business policies, and strategies, providing invaluable insights into the key trends and breakthroughs in the market. Additionally, the report has carefully scrutinized the market share of the top segments and presented a detailed geographic analysis. Finally, the report has highlighted the major players in the industry and their ongoing endeavors to develop innovative solutions that cater to the ever-increasing demand for Diabetes Care Devices.

Speak to Analyst for your custom requirements:

https://www.skyquestt.com/speak-with-analyst/diabetes-care-devices-and-drugs-market

Key Developments in Diabetes Care Devices Market

  • In May 2023, Medtronic, a renowned player in healthcare technology, revealed its strategic move to acquire EOFlow Co. Ltd. EOFlow is the maker of the innovative EOPatch® device, which is a completely disposable, wearable insulin delivery device that operates without tubes.

Key Questions Answered in Diabetes Care Devices Market Report

  • What specific growth drivers are projected to impact the market during the forecast period?
  • Can you list the top companies in the market and explain how they have achieved their positions of influence?
  • In what ways do regional trends and patterns differ within the global market, and how might these differences shape the market’s future growth?

Related Reports in SkyQuest’s Library:

Global Medical Animation Market

Global Radiodermatitis Market

Global Sleep Tech Devices Market

Global Orthopaedic Software Market

Global Neuroendoscopy Devices Market

About Us:

SkyQuest Technology is leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email: sales@skyquestt.com

LinkedIn Facebook Twitter

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.